5- [4- (azetidin-3-yl0xy) -phenyl] - 2-phenyl-5H-thiaz0l0 [5,4-c] pyridin4-0ne derivatives and their use as MCH receptor antagonists

Details for Australian Patent Application No. 2007334171 (hide)

Owner Eli Lilly and Company

Inventors Szekeres, Helen Jane; Hembre, Erik James; Garmene, David Joseph; Brunavs, Michael; Gardinier, Kevin Matthew

Agent Spruson & Ferguson

Pub. Number AU-A-2007334171

PCT Pub. Number WO2008/076562

Priority 60/870,011 14.12.06 US

Filing date 15 November 2007

Wipo publication date 26 June 2008

International Classifications

C07D 513/04 (2006.01) Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or

A61K 31/437 (2006.01)

Event Publications

11 June 2009 PCT application entered the National Phase

  PCT publication WO2008/076562 Priority application(s): WO2008/076562

13 August 2009 Amendment Made

  The nature of the amendment is: Amend the invention title to read 5- [4- (azetidin-3-yloxy) -phenyl] - 2-phenyl-5H-thiazolo [5,4-c] pyridin-4-one derivatives and their use as MCH receptor antagonists

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007334213-Bone growth particles and osteoinductive composition thereof

2007334162-Method and apparatus for assisting deglutition